Re-administration of a combination of chemotherapy + Gemtuzumab at relapse in CD33+ AML patient allows to second remission and is feasible without extra toxicity.
As combination of chemotherapy and Gemtuzumab may become a common induction regimen for CD33+ AML patients, there is no report assessing the safety and toxicity of a re-treatment at relapse with such combination in a same patient. Here we describe the case of a 69-year-old patient who achieved a second complete remission with this association without additional toxicity.
Chevallier
Patrice
P
Department of Hematology, Centre Hospitalier Universitaire, Nantes, France. patrice.chevalier@chu-nantes.fr
Touzeau
Cyril
C
Ayari
Sameh
S
Guillaume
Thierry
T
Harousseau
Jean-Luc
JL
Delaunay
Jacques
J
D000368:Aged; D000617:Aminoglycosides / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000032:analysis*; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis*; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D005240:Feasibility Studies; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D012074:Remission Induction; D063268:Sialic Acid Binding Ig-like Lectin 3
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000970:Antineoplastic Agents; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab